NDAINHALATIONGAS
Approved
Aug 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
HELIUM, USP (helium) by Advanced Solutions Life Sciences. Approved for aortic valve stenosis, asthma, obesity and 1 more indications. First approved in 2019.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HELIUM, USP is an inhaled gas therapeutic approved in 2019 for aortic valve stenosis, asthma, obesity, and metabolic syndrome. The product operates as a gas dosage form with no disclosed pharmacologic mechanism of action or drug class. It represents an unconventional modality in the pharmaceutical landscape, targeting multiple therapeutic areas through inhalation delivery.
Peak
Product is at peak lifecycle stage with moderate competitive pressure (30), suggesting stable revenue trajectory and established brand team operations.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on HELIUM, USP at Advanced Solutions Life Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.